| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2005-05-1778 |
| P8608 | Fatcat ID | release_ku5cbi5prfckfonn5y75kbq4k4 |
| P932 | PMC publication ID | 1895235 |
| P698 | PubMed publication ID | 16131571 |
| P5875 | ResearchGate publication ID | 7628542 |
| P50 | author | Donna Neuberg | Q87319577 |
| Lecia V Sequist | Q90926732 | ||
| Lee M. Nadler | Q117474702 | ||
| Jerome Ritz | Q41590860 | ||
| P2093 | author name string | Edwin P Alyea | |
| Peter Mauch | |||
| Robert J Soiffer | |||
| Robert Schlossman | |||
| John G Gribben | |||
| David Zahrieh | |||
| Arnold S Freedman | |||
| David C Fisher | |||
| Blossom Marshall | |||
| Katherine Stephans | |||
| Lini Bartlett-Pandite | |||
| P2860 | cites work | Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia | Q28140129 |
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia | Q30585311 | ||
| Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia | Q33455289 | ||
| Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. | Q33478625 | ||
| Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases | Q33682722 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| Familial chronic lymphocytic leukaemia: a survey and review of published studies | Q33992813 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment | Q34382878 | ||
| Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation | Q34532323 | ||
| Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia | Q34662857 | ||
| Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect | Q35597067 | ||
| Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies | Q35994909 | ||
| Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? | Q36292975 | ||
| Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy | Q40701090 | ||
| Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group | Q41262857 | ||
| High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. | Q44311992 | ||
| Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia | Q46421462 | ||
| Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. | Q47324610 | ||
| The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status | Q47325357 | ||
| HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. | Q53369393 | ||
| Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. | Q54017366 | ||
| Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma | Q58415161 | ||
| Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses | Q61868167 | ||
| Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities | Q68535307 | ||
| Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance | Q70026398 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation | Q71571103 | ||
| Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia | Q72091476 | ||
| Second cancers in patients with Ewing's sarcoma | Q72240881 | ||
| Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results | Q72348188 | ||
| Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress | Q72521371 | ||
| Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia | Q72779951 | ||
| CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission | Q73235563 | ||
| Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia | Q73642992 | ||
| Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant | Q74511297 | ||
| Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia | Q78460516 | ||
| Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis | Q81649289 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphocyte | Q715347 |
| leukemia | Q29496 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 4389-4396 | |
| P577 | publication date | 2005-08-30 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia | |
| P478 | volume | 106 |
| Q53326016 | A 23-year-old woman with 11q-chronic lymphocytic leukemia. |
| Q41438622 | Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells |
| Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
| Q34549285 | Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when? |
| Q85536716 | Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse |
| Q34549313 | Allogeneic transplantation for chronic lymphocytic leukemia |
| Q37738604 | Assessing minimal residual disease in chronic lymphocytic leukemia |
| Q41986069 | Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over? |
| Q83339318 | Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience |
| Q84496850 | Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial |
| Q46925369 | Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. |
| Q34879367 | Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 |
| Q80932425 | Chronic lymphocytic leukaemia |
| Q36712736 | Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q36913228 | Chronic lymphocytic leukemia: biology and current treatment |
| Q37802570 | Definition of a Target for Immunotherapy and Results of the First Peptide Vaccination Study in Chronic Lymphocytic Leukemia |
| Q36883352 | Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study |
| Q37832506 | Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation |
| Q38103578 | Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies |
| Q43135383 | Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). |
| Q36981738 | Emerging therapy for chronic lymphocytic leukaemia |
| Q37738532 | Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? |
| Q37738606 | Eradication of minimal residual disease in chronic lymphocytic leukemia |
| Q47218376 | Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers |
| Q37119402 | Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning |
| Q24645173 | Fludarabine in the treatment of chronic lymphocytic leukemia: a review |
| Q34531834 | Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. |
| Q80866767 | Genetically identical twin transplantation for chronic lymphocytic leukemia |
| Q36223667 | Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia |
| Q36843780 | Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia |
| Q53249666 | Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd-25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies. |
| Q37445265 | Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation |
| Q36745408 | Graft-versus-leukemia in chronic lymphocytic leukemia |
| Q24616084 | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines |
| Q34985471 | HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). |
| Q88312666 | HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy |
| Q27021206 | Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens |
| Q86661128 | Hematopoietic stem cell transplantation |
| Q36416452 | Hematopoietic stem cell transplantation for chronic lymphocytic leukemia |
| Q37012037 | Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease |
| Q44580107 | High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. |
| Q34137158 | How I treat CLL up front |
| Q88645380 | How and when I do allogeneic transplant in CLL |
| Q38340201 | How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? |
| Q38840989 | Immunoselection techniques in hematopoietic stem cell transplantation |
| Q26768154 | Immunotherapy in Chronic Lymphocytic Leukaemia (CLL) |
| Q38098957 | Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies |
| Q36654926 | Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. |
| Q36460415 | Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome |
| Q53453511 | Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. |
| Q34769213 | Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? |
| Q36665330 | Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q40640735 | Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience |
| Q36384668 | Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia |
| Q36692782 | Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome |
| Q35563832 | Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure |
| Q38259446 | Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. |
| Q37175581 | Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation |
| Q81505678 | Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology |
| Q81100907 | Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial |
| Q46077879 | Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. |
| Q84453753 | Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience |
| Q45344362 | Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients |
| Q34348572 | Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review |
| Q41191932 | Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation |
| Q33779931 | Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. |
| Q37824996 | Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia |
| Q24642921 | Stem cell transplantation in chronic lymphocytic leukemia |
| Q36952609 | Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence? |
| Q36965455 | Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia |
| Q62735936 | The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis |
| Q38355743 | The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. |
| Q36962654 | The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia |
| Q36849336 | The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia |
| Q37439565 | The role of stem cell transplantation in the management of chronic lymphocytic leukaemia |
| Q35153656 | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia |
| Q37738522 | Transplantation in chronic lymphocytic leukemia |
| Q34625543 | Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? |
| Q36714741 | Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century |
| Q36634599 | Update on risk-stratified management for chronic lymphocytic leukemia |
| Q37659071 | Update on therapy of chronic lymphocytic leukemia |
Search more.